Halozyme Therapeutics retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $0.398B, a 78.88% increase year-over-year.
Halozyme Therapeutics retained earnings (accumulated deficit) for 2023 were $0.091B, a 36.77% decline from 2022.
Halozyme Therapeutics retained earnings (accumulated deficit) for 2022 were $0.143B, a 343.1% decline from 2021.
Halozyme Therapeutics retained earnings (accumulated deficit) for 2021 were $-0.059B, a 87.59% decline from 2020.